OncoTherapy Science (TSE:4564) Tariff Resilience Score: 0/10 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円20.00
GF Value 円16.92
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Tariff Resilience Score?

OncoTherapy Science has the Tariff Resilience Score of 0, which implies that the company might have .

OncoTherapy Science has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes OncoTherapy Science might have .


OncoTherapy Science  (TSE:4564) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

OncoTherapy Science Tariff Resilience Score Related Terms

TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円20.00 is trading 18.2% above its estimated GF Value™ of 円16.92. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • Tariff Resilience Score: 0
  • GF Value™: 円16.92 vs. price of 円20.00 (18.2% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円20.00
Price
円16.92
GF Value